Miltefosine

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Litigation free, first generic opportunities!

Wouldn’t it just be wonderful if there were opportunities to become the first generic on the m